Literature DB >> 2842252

Multiple autoantibodies following cytomegalovirus infection: virus distribution and specificity of autoantibodies.

W N Bartholomaeus1, H O'Donoghue, D Foti, C M Lawson, G R Shellam, W D Reed.   

Abstract

Multiple autoantibodies were found in the sera of BALB/c, C57BL/10 and C3H mice following mouse cytomegalovirus (MCMV) infection. The complex pattern of intra-organ, intratissue and intracellular reactivity observed by immunoperoxidase histochemistry suggested that many autoantibodies of varying specificities were elicited. This evidence from immunoperoxidase histochemistry was confirmed by immunoblot, where autoantibodies binding to polypeptides of a variety of sizes and tissues of origin were observed. In addition to these central findings, the tissue and organ distribution of MCMV in three mouse strains of differing genetic resistance were described. No correlation was found between the distribution of virus and the tissue and organ specificity of the autoantibodies produced following infection. Inflammatory responses accompanied MCMV infection in a number of tissues. In BALB/c mice, myocarditis and salivary gland inflammation were evident at Day 56 post-infection in the absence of MCMV, but in the presence of autoantibodies to cardiac muscle and salivary duct epithelium. This model for virus-induced autoimmunity can be applied to studies of the relationship between virus infection, autoimmunity and disease.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2842252      PMCID: PMC1385049     

Source DB:  PubMed          Journal:  Immunology        ISSN: 0019-2805            Impact factor:   7.397


  29 in total

1.  Infection of salivary glands, kidneys, adrenals, ovaries and epithelia by murine cytomegalovirus.

Authors:  C A Mims; J Gould
Journal:  J Med Microbiol       Date:  1979-02       Impact factor: 2.472

2.  Smooth-muscle antibodies and other tissue antibodies in cytomegalovirus infection.

Authors:  P Andersen; H K Andersen
Journal:  Clin Exp Immunol       Date:  1975-10       Impact factor: 4.330

3.  The relationship between liver-specific lipoprotein and the hepatocyte plasma membrane.

Authors:  W N Bartholomaeus; N R Swanson; W D Reed; H L O'Donoghue; D Foti; J M Papadimitriou
Journal:  Immunology       Date:  1987-03       Impact factor: 7.397

4.  The role of macrophages in mice infected with murine cytomegalovirus.

Authors:  C A Mims; J Gould
Journal:  J Gen Virol       Date:  1978-10       Impact factor: 3.891

5.  Cytomegalovirus-induced immune suppression. I. Humoral immunity.

Authors:  R J Howard; J S Najarian
Journal:  Clin Exp Immunol       Date:  1974-09       Impact factor: 4.330

6.  Mixed cryoimmunoglobulinaemia in infectious mononucleois and Cytomegalovirus mononucleosis.

Authors:  O Wager; J A Räsänen; A Hagman; E Klemola
Journal:  Int Arch Allergy Appl Immunol       Date:  1968

7.  Influence of H-2 and non-H-2 genes on resistance to murine cytomegalovirus infection.

Authors:  J E Grundy; J S Mackenzie; N F Stanley
Journal:  Infect Immun       Date:  1981-04       Impact factor: 3.441

8.  Enhanced immune response late in primary cytomegalovirus infection of mice.

Authors:  T J Tinghitella; J Booss
Journal:  J Immunol       Date:  1979-06       Impact factor: 5.422

9.  Resistance to murine cytomegalovirus linked to the major histocompatibility complex of the mouse.

Authors:  J E Chalmer; J S Mackenzie; N F Stanley
Journal:  J Gen Virol       Date:  1977-10       Impact factor: 3.891

10.  Pathogenesis of cytomegalovirus infection. Distribution of viral products, immune complexes and autoimmunity during latent murine infection.

Authors:  L B Olding; D T Kingsbury; M B Oldstone
Journal:  J Gen Virol       Date:  1976-11       Impact factor: 3.891

View more
  24 in total

1.  Failure of antiviral therapy in AIDS-associated cytomegalovirus cholangitis.

Authors:  M E van der Ende; A C van Buuren; A C Kroes; F J ten Kate
Journal:  Infection       Date:  1992 Nov-Dec       Impact factor: 3.553

2.  Cytomegalovirus-induced pneumonitis and myocarditis in newborn mice. A model for perinatal human cytomegalovirus infection.

Authors:  N A Fitzgerald; J M Papadimitriou; G R Shellam
Journal:  Arch Virol       Date:  1990       Impact factor: 2.574

3.  Autoantibodies to cardiac myosin in mouse cytomegalovirus myocarditis.

Authors:  H L O'Donoghue; C M Lawson; W D Reed
Journal:  Immunology       Date:  1990-09       Impact factor: 7.397

Review 4.  Immunological tolerance as a barrier to protective HIV humoral immunity.

Authors:  Kristin Ms Schroeder; Amanda Agazio; Raul M Torres
Journal:  Curr Opin Immunol       Date:  2017-07-17       Impact factor: 7.486

5.  Type I interferon gene therapy protects against cytomegalovirus-induced myocarditis.

Authors:  Vanessa S Cull; Emmalene J Bartlett; Cassandra M James
Journal:  Immunology       Date:  2002-07       Impact factor: 7.397

Review 6.  Autoimmune polyglandular syndrome Type 2: the tip of an iceberg?

Authors:  C Betterle; F Lazzarotto; F Presotto
Journal:  Clin Exp Immunol       Date:  2004-08       Impact factor: 4.330

7.  An attenuated variant of Coxsackievirus B3 preferentially induces immunoregulatory T cells in vivo.

Authors:  R P Loudon; A F Moraska; S A Huber; P Schwimmbeck; P Schultheiss
Journal:  J Virol       Date:  1991-11       Impact factor: 5.103

8.  Induction of HLA-DR expression on thyroid follicular cells by cytomegalovirus infection in vitro. Evidence for a dual mechanism of induction.

Authors:  E L Khoury; L Pereira; F S Greenspan
Journal:  Am J Pathol       Date:  1991-05       Impact factor: 4.307

9.  Murine anti-cytomegalovirus monoclonal antibodies with autoreactivity.

Authors:  C M Lawson; H L O'Donoghue; H E Farrell; G R Shellam; W D Reed
Journal:  Immunology       Date:  1991-03       Impact factor: 7.397

10.  Wild isolates of murine cytomegalovirus induce myocarditis and antibodies that cross-react with virus and cardiac myosin.

Authors:  D Fairweather; C M Lawson; A J Chapman; C M Brown; T W Booth; J M Papadimitriou; G R Shellam
Journal:  Immunology       Date:  1998-06       Impact factor: 7.397

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.